Rational Design of Highly Potent SARS-CoV-2 nsp14 Methyltransferase Inhibitors

Area of Science:

• Medicinal Chemistry
• Virology
• Drug Discovery

Background:

• COVID-19 pandemic necessitates new antiviral therapies.
• Targeting viral RNA capping machinery is a potential therapeutic strategy.
• SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) nsp14 protein mediates essential RNA methylation.

Purpose of the Study:

• To design and synthesize novel compounds targeting the SARS-CoV-2 nsp14 N7-methyltransferase.
• To evaluate the in vitro potency, selectivity, and cell permeability of these compounds.
• To investigate the role of nsp14 methyltransferase activity in viral replication and pathogenesis.

Main Methods:

• Rational drug design and chemical synthesis of hybrid molecules.
• Biochemical assays to assess enzyme inhibition and selectivity against human methyltransferases.
• In vitro antiviral assays to determine efficacy against SARS-CoV-2.
• Cell permeability and toxicity assessments.

Main Results:

• Synthesized compounds effectively bound to both S-adenosyl-l-methionine and RNA-binding sites of nsp14.
• Compounds demonstrated excellent enzyme inhibition potency and high selectivity against human methyltransferases.
• Nontoxicity and high cell permeability were observed.
• Despite potent enzyme inhibition, compounds exhibited poor in vitro antiviral activity.

Conclusions:

• The SARS-CoV-2 nsp14 methyltransferase activity may not be essential for viral transcription and replication in cells.
• The designed compounds are valuable chemical probes for further research into nsp14 function.
• This study provides insights into the limited impact of targeting this specific enzyme for COVID-19 treatment.